Akram Abu-Okail

Akram Abu-Okail

Faculty of Veterinary Medicine

Department of Clinical Pathology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt

Profile ID RP-003-2281 Joined 2025-04-03 16 articles
0Connections
7
Total Views
16
Total Publications
283
Publication Views

About me

Akram Abu-Okail is currently a PhD researcher at Cairo University, Faculty of Veterinary Medicine, Department of Clinical Pathology. Akram is a M.Sc. graduated student from Qassim University, College of Veterinary Medicine, Department of Pathology and Laboratory Diagnosis, Laboratory Diagnosis Program. Akram does research in Clinical and Molecular Pathology. I am looking for potential International collaborators to work on joint research projects on clinical and molecular pathology.

Articles(16)

Authors: Ayman Elbehiry, Eman Marzouk, Musaad Aldubaib, Adil Abalkhail, Sulaiman Anagreyyah, Nuha Anajirih, Abdulaziz M. Almuzaini, Mohammed Rawway, Abdulmajeed Alfadhel, Abdelmaged Draz, Akram Abu-Okail

DOI: 10.3390/antibiotics12020191

Volume12
Issue2
Pages191
Abstract

Helicobacter pylori (H. pylori) infection, which affects approximately half of the world’s population, remains a serious public health problem. As H. pylori infection leads to a number of gastric pathologies, including inflammation, gastroduodenal ulcers, and malignancies, early detection and treatment are crucial to preventing the spread of the infection. Multiple extragastric complications, such as iron deficiency anaemia, immune thrombocytopenic purpura, vitamin B12 deficiency, diabetes mellitus, cardiovascular diseases, and certain neurological disorders, have also been linked to H. pylori infection. An awareness of H. pylori and associated health hazards is necessary to minimize or even eradicate the infection. Therefore, there is an urgent need to raise the standards for the currently employed diagnostic, eradication, alternative treatment strategies. In addition, a brief overview of traditional and cutting-edge approaches that have proven effective in identifying and managing H. pylori is needed. Based on the test and laboratory equipment available and patient clinical characteristics, the optimal diagnostic approach requires weighing several factors. The pathophysiology and pathogenic mechanisms of H. pylori should also be studied, focusing more on the infection-causing virulence factors of this bacterium. Accordingly, this review aims to demonstrate the various diagnostic, pathophysiological, therapeutic, and eradication tactics available for H. pylori, emphasizing both their advantages and disadvantages. Invasive methods (such as quick urease testing, biopsy, or culture) or noninvasive methods (such as breath tests, stool investigations, or serological tests) can be used. We also present the most recent worldwide recommendations along with scientific evidence for treating H. pylori. In addition to the current antibiotic regimens, alternative therapies may also be considered. It is imperative to eradicate the infections caused by H. pylori as soon as possible to prevent problems and the development of stomach cancer. In conclusion, significant advances have been made in identifying and treating H. pylori. To improve eradication rates, peptide mass fingerprinting can be used as a diagnostic tool, and vaccines can also eliminate the infection.

Authors: Ayman Elbehiry, Adil Abalkhail, Eman Marzouk, Ahmed Elnadif Elmanssury, Abdulaziz M. Almuzaini, Hani Alfheeaid, Mohammed T. Alshahrani, Nasser Huraysh, Mai Ibrahem, Feras Alzaben, Farhan Alanazi, Mohammed Alzaben, Sulaiman Abdulaziz Anagreyyah, Abdul

DOI: 10.3390/vaccines11040725

Volume11
Issue4
Pages725
Abstract

Pathogens found in food are believed to be the leading cause of foodborne illnesses; and they are considered a serious problem with global ramifications. During the last few decades, a lot of attention has been paid to determining the microorganisms that cause foodborne illnesses and developing new methods to identify them. Foodborne pathogen identification technologies have evolved rapidly over the last few decades, with the newer technologies focusing on immunoassays, genome-wide approaches, biosensors, and mass spectrometry as the primary methods of identification. Bacteriophages (phages), probiotics and prebiotics were known to have the ability to combat bacterial diseases since the turn of the 20th century. A primary focus of phage use was the development of medical therapies; however, its use quickly expanded to other applications in biotechnology and industry. A similar argument can be made with regards to the food safety industry, as diseases directly endanger the health of customers. Recently, a lot of attention has been paid to bacteriophages, probiotics and prebiotics most likely due to the exhaustion of traditional antibiotics. Reviewing a variety of current quick identification techniques is the purpose of this study. Using these techniques, we are able to quickly identify foodborne pathogenic bacteria, which forms the basis for future research advances. A review of recent studies on the use of phages, probiotics and prebiotics as a means of combating significant foodborne diseases is also presented. Furthermore, we discussed the advantages of using phages as well as the challenges they face, especially given their prevalent application in food safety.

Authors: Ayman Elbehiry, Eman Marzouk, Ihab Moussa, Yazeed Mushayt, Ahmad Abdullah Algarni, Osama Ali Alrashed, Khalid Saad Alghamdi, Naif Ahmed Almutairi, Sulaiman Abdulaziz Anagreyyah, Anwar Alzahrani, Abdulaziz M. Almuzaini, Feras Alzaben, Meshal Abdullah

DOI: 10.3390/vaccines11071171

Volume11
Issue7
Pages1171
Abstract

There is growing concern among healthcare providers worldwide regarding the prevalence of multidrug-resistant Acinetobacter baumannii (A. baumannii). Some of the worst hospital-acquired infections, often in intensive care units (ICUs), are caused by this bacterial pathogen. In recent years, the rise in multidrug-resistant A. baumannii has been linked to the overuse of antimicrobial drugs and the lack of adequate infection control measures. Infections caused by this bacterial pathogen are the result of prolonged hospitalization and ICU stays, and they are associated with increased morbidity and mortality. This review outlines the epidemiology, risk factors, and antimicrobial resistance associated with A. baumannii in various countries, with a special focus on the Kingdom of Saudi Arabia. In response to the growing concern regarding this drug-resistant bacteria, fundamental information about its pathology has been incorporated into the development of vaccines. Although these vaccines have been successful in animal models, their effectiveness in humans remains unproven. The review will discuss the development of A. baumannii vaccines, potential related obstacles, and efforts to find an effective strategy against this pathogen.

Authors: Ehab Kotb Elmahallawy, Ahmed Gareh, Akram Abu-Okail, Pamela C. Köster, Alejandro Dashti, Jamal Asseri, Asmaa Aboelabbas Gouda, Murad A. Mubaraki, Sara Abdel-Aal Mohamed, Yasser M. Mohamed, Ehssan Ahmed Hassan, Mohamed Elgendy, Carolina Hernández-Cast

DOI: 10.3389/fvets.2023.1229151

Volume10
Issue1
Pages1
Abstract

IntroductionDomestic dogs and cats can be a source of human infection by a wide diversity of zoonotic pathogens including parasites. Genotyping and subtyping tools are useful in assessing the true public health relevance of canine and feline infections by these pathogens. This study investigated the occurrence, genetic diversity, and zoonotic potential of common diarrhea-causing enteric protist parasites in household dogs and cats in Egypt, a country where this information is particularly scarce.MethodsIn this prospective, cross-sectional study a total of 352 individual fecal samples were collected from dogs (n = 218) and cats (n = 134) in three Egyptian governorates (Dakahlia, Gharbeya, and Giza) during July–December 2021. Detection and identification of Cryptosporidium spp., Giardia duodenalis, Enterocytozoon bieneusi, and Blastocystis sp. were carried out by PCR and Sanger sequencing. Basic epidemiological variables (geographical origin, sex, age, and breed) were examined for association with occurrence of infection by enteric protists.Results and discussionThe overall prevalence rates of Cryptosporidium spp. and G. duodenalis were 1.8% (95% CI: 0.5–4.6) and 38.5% (95% CI: 32.0–45.3), respectively, in dogs, and 6.0% (95% CI: 2.6–11.4) and 32.1% (95% CI: 24.3–40.7), respectively, in cats. All canine and feline fecal samples analyzed tested negative for E. bieneusi and Blastocystis sp. Dogs from Giza governorate and cats from Dakahlia governorate were at higher risk of infection by Cryptosporidium spp. (p = 0.0006) and G. duodenalis (p = 0.00001), respectively. Sequence analyses identified host-adapted Cryptosporidium canis (n = 4, one of them belonging to novel subtype XXe2) and G. duodenalis assemblages C (n = 1) and D (n = 3) in dogs. In cats the zoonotic C. parvum (n = 5) was more prevalent than host-adapted C. felis (n = 1). Household dogs had a limited (but not negligible) role as source of human giardiasis and cryptosporidiosis, but the unexpected high frequency of zoonotic C. parvum in domestic cats might be a public health concern. This is the first molecular-based description of Cryptosporidium spp. infections in cats in the African continent to date. Molecular epidemiological data provided here can assist health authorities and policy makers in designing and implementing effective campaigns to minimize the transmission of enteric protists in Egypt.

Authors: Ayman Elbehiry, Eman Marzouk, Ihab Moussa, Sulaiman Anagreyyah, Abdulaziz AlGhamdi, Ali Alqarni, Ahmed Aljohani, Hassan A. Hemeg, Abdulaziz M. Almuzaini, Feras Alzaben, Adil Abalkhail, Roua A. Alsubki, Ali Najdi, Nawaf Algohani, Banan Abead, Bassam G

DOI: 10.3390/diagnostics13172825

Volume13
Issue17
Pages2825
Abstract

In hospitals and other clinical settings, Methicillin-resistant Staphylococcus aureus (MRSA) is a particularly dangerous pathogen that can cause serious or even fatal infections. Thus, the detection and differentiation of MRSA has become an urgent matter in order to provide appropriate treatment and timely intervention in infection control. To ensure this, laboratories must have access to the most up-to-date testing methods and technology available. This study was conducted to determine whether protein fingerprinting technology could be used to identify and distinguish MRSA recovered from both inpatients and outpatients. A total of 326 S. aureus isolates were obtained from 2800 in- and outpatient samples collected from King Faisal Specialist Hospital and Research Centre in Riyadh, Saudi Arabia, from October 2018 to March 2021. For the phenotypic identification of 326 probable S. aureus cultures, microscopic analysis, Gram staining, a tube coagulase test, a Staph ID 32 API system, and a Vitek 2 Compact system were used. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), referred to as protein fingerprinting, was performed on each bacterial isolate to determine its proteomic composition. As part of the analysis, Principal Component Analysis (PCA) and a single-peak analysis of MALDI-TOF MS software were also used to distinguish between Methicillin-sensitive Staphylococcus aureus (MSSA) and MRSA. According to the results, S. aureus isolates constituted 326 out of 2800 (11.64%) based on the culture technique. The Staph ID 32 API system and Vitek 2 Compact System were able to correctly identify 262 (80.7%) and 281 (86.2%) S. aureus strains, respectively. Based on the Oxacillin Disc Diffusion Method, 197 (62.23%) of 326 isolates of S. aureus exhibited a cefoxitin inhibition zone of less than 21 mm and an oxacillin inhibition zone of less than 10 mm, and were classified as MRSA under Clinical Laboratory Standards Institute guidelines. MALDI-TOF MS was able to correctly identify 100% of all S. aureus isolates with a score value equal to or greater than 2.00. In addition, a close relationship was found between S. aureus isolates and higher peak intensities in the mass ranges of 3990 Da, 4120 Da, and 5850 Da, which were found in MRSA isolates but absent in MSSA isolates. Therefore, protein fingerprinting has the potential to be used in clinical settings to rapidly detect and differentiate MRSA isolates, allowing for more targeted treatments and improved patient outcomes.

Authors: Ayman Elbehiry, Mansor Al Shoaibi, Hamzah Alzahrani, Mai Ibrahem, Ihab Moussa, Feras Alzaben, Rousa A. Alsubki, Hassan A. Hemeg, Dakheel Almutairi, Saleh Althobaiti, Fawaz Alanazi, Sultan A. Alotaibi, Hamoud Almutairi, Ali Alzahrani, Akram Abu-Okail

DOI: 10.1186/s13568-024-01675-7

Volume14
Issue1
Pages1
Abstract

AbstractThe genus Enterobacter belongs to the ESKAPE group, which includes Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. This group is characterized by the development of resistance to various antibiotics. In recent years, Enterobacter cloacae (E. cloacae) has emerged as a clinically important pathogen responsible for a wide range of healthcare-associated illnesses. Identifying Enterobacter species can be challenging due to their similar phenotypic characteristics. The emergence of multidrug-resistant E. cloacae is also a significant problem in healthcare settings. Therefore, our study aimed to identify and differentiate E. cloacae using Matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) as a fast and precise proteomic analytical technique. We also tested hospital-acquired E. cloacae isolates that produce Extended-spectrum beta-lactamases (ESBL) against commonly used antibiotics for treating urinary tract infections (UTIs). We used a total of 189 E. cloacae isolates from 2300 urine samples of patients with UTIs in our investigation. We employed culturing techniques, as well as the BD Phoenix™ automated identification system (Becton, Dickinson) and Analytical Profile Index (API) system for the biochemical identification of E. cloacae isolates. We used the MALDI Biotyper (MBT) device for peptide mass fingerprinting analysis of all isolates. We utilized the single peak intensities and Principal Component Analysis (PCA) created by MBT Compass software to discriminate and cluster the E. cloacae isolates. Additionally, we evaluated the sensitivity and resistance of ESBL-E. cloacae isolates using the Kirby Bauer method. Out of the 189 E. cloacae isolates, the BD Phoenix system correctly identified 180 (95.24%) isolates, while the API system correctly identified 165 (87.30%) isolates. However, the MBT accurately identified 185 (98.95%) isolates with a score of 2.00 or higher. PCA positively discriminated the identified E. cloacae isolates into one group, and prominent peaks were noticed between 4230 mass-to-charge ratio (m/z) and 8500 m/z. The ESBL-E. cloacae isolates exhibited a higher degree of resistance to ampicillin, amoxicillin-clavulanate, cephalothin, cefuroxime, and cefoxitin. Several isolates were susceptible to carbapenems (meropenem, imipenem, and ertapenem); however, potential future resistance against carbapenems should be taken into consideration. In conclusion, MALDI-TOF MS is a powerful and precise technology that can be routinely used to recognize and differentiate various pathogens in clinical samples. Additionally, the growing antimicrobial resistance of this bacterium may pose a significant risk to human health.

Authors: Eman Marzouk, Adil Abalkhail, Jamaan ALqahtani, Khalid Alsowat, Menwer Alanazi, Feras Alzaben, Abdulaziz Alnasser, Anas Alasmari, Mohammed Rawway, Abdelmaged Draz, Akram Abu-Okail, Abdulmohsen Altwijery, Ihab Moussa, Sulaiman Alsughayyir, Saleh Alamr

DOI: 10.1186/s13568-024-01710-7

Volume14
Issue1
Pages1
Abstract

AbstractKlebsiella pneumoniae (K. pneumoniae) is a member of the ESKAPE group and is responsible for severe community and healthcare-associated infections. Certain Klebsiella species have very similar phenotypes, which presents a challenge in identifying K. pneumoniae. Multidrug-resistant K. pneumoniae is also a serious global problem that needs to be addressed. A total of 190 isolates were isolated from urine (n = 69), respiratory (n = 52), wound (n = 48) and blood (n = 21) samples collected from various hospitals in the Al-Qassim, Saudi Arabia, between March 2021 and October 2022. Our study aimed to rapidly and accurately detect K. pneumoniae using the Peptide Mass Fingerprinting (PMF) technique, confirmed by real-time PCR. Additionally, screening for antibiotic susceptibility and resistance was conducted. The primary methods for identifying K. pneumoniae isolates were culture, Gram staining, and the Vitek® 2 ID Compact system. An automated MALDI Biotyper (MBT) instrument was used for proteome identification, which was subsequently confirmed using SYBR green real-time polymerase chain reaction (real-time PCR) and microfluidic electrophoresis assays. Vitek® 2 AST-GN66 cards were utilized to evaluate the antimicrobial sensitivity of K. pneumoniae isolates. According to our results, Vitek® 2 Compact accurately identified 178 out of 190 (93.68%) K. pneumoniae isolates, while the PMF technique correctly detected 188 out of 190 (98.95%) isolates with a score value of 2.00 or higher. Principal component analysis was conducted using MBT Compass software to classify K. pneumoniae isolates based on their structure. Based on the analysis of the single peak intensities generated by MBT, the highest peak values were found at 3444, 5022, 5525, 6847, and 7537 m/z. K. pneumoniae gene testing confirmed the PMF results, with 90.53% detecting entrobactin, 70% detecting 16 S rRNA, and 32.63% detecting ferric iron uptake. The resistance of the K. pneumoniae isolates to antibiotics was as follows: 64.75% for cefazolin, 62.63% for trimethoprim/sulfamethoxazole, 59.45% for ampicillin, 58.42% for cefoxitin, 57.37% for ceftriaxone, 53.68% for cefepime, 52.11% for ampicillin-sulbactam, 50.53% for ceftazidime, 52.11% for ertapenem, and 49.47% for imipenem. Based on the results of the double-disk synergy test, 93 out of 190 (48.95%) K. pneumoniae isolates were extended-spectrum beta-lactamase. In conclusion, PMF is a powerful analytical technique used to identify K. pneumoniae isolates from clinical samples based on their proteomic characteristics. K. pneumoniae isolates have shown increasing resistance to antibiotics from different classes, including carbapenem, which poses a significant threat to human health as these infections may become difficult to treat.

Authors: Ayman Elbehiry, Eman Marzouk, Adil Abalkhail, Wael Sindi, Yasir Alzahrani, Salem Alhifani, Turki Alshehri, Nuha Abdulaziz Anajirih, Turki ALMutairi, Ahmad Alsaedi, Feras Alzaben, Abdullah Alqrni, Abdelmaged Draz, Abdulaziz M. Almuzaini, Sahar N. Alja

DOI: 10.3389/fmed.2024.1523991

Volume11
Issue1
Pages1
Abstract

One of the most prevalent human infections is Helicobacter pylori (H. pylori), which affects more than half of the global population. Although H. pylori infections are widespread, only a minority of individuals develop severe gastroduodenal disorders. The global resistance of H. pylori to antibiotics has reached concerning levels, significantly impacting the effectiveness of treatment. Consequently, the development of vaccines targeting virulence factors may present a viable alternative for the treatment and prevention of H. pylori infections. This review aims to provide a comprehensive overview of the current understanding of H. pylori infection, with a particular focus on its virulence factors, pathophysiology, and vaccination strategies. This review discusses various virulence factors associated with H. pylori, such as cytotoxin-associated gene A (cagA), vacuolating cytotoxin gene (vacA), outer membrane proteins (OMPs), neutrophil-activated protein (NAP), urease (ure), and catalase. The development of vaccines based on these virulence characteristics is essential for controlling infection and ensuring long-lasting protection. Various vaccination strategies and formulations have been tested in animal models; however, their effectiveness and reproducibility in humans remain uncertain. Different types of vaccines, including vector-based vaccines, inactivated whole cells, genetically modified protein-based subunits, and multiepitope nucleic acid (DNA) vaccines, have been explored. While some vaccines have demonstrated promising results in murine models, only a limited number have been successfully tested in humans. This article provides a thorough evaluation of recent research on H. pylori virulence genes and vaccination methods, offering valuable insights for future strategies to address this global health challenge.

Authors: Ayman Elbehiry, Eman Marzouk, Adil Abalkhail, Moustafa H. Abdelsalam, Mohamed E. A. Mostafa, Mazen Alasiri, Mai Ibrahem, Abousree T. Ellethy, Abdulaziz Almuzaini, Sahar N. Aljarallah, Akram Abu-Okail, Naif Marzook, Satam Alhadyan, Husam M. Edrees

DOI: 10.3389/fmicb.2025.1549044

Volume16
Issue1
Pages1
Abstract

Antimicrobial resistance (AMR) is recognized as one of the foremost global health challenges, complicating the treatment of infectious diseases and contributing to increased morbidity and mortality rates. Traditionally, microbiological culture and susceptibility testing methods, such as disk diffusion and minimum inhibitory concentration (MIC) assays, have been employed to identify AMR bacteria. However, these conventional techniques are often labor intensive and time consuming and lack the requisite sensitivity for the early detection of resistance. Recent advancements in molecular and genomic technologies—such as next-generation sequencing (NGS), matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS), lateral flow immunoassays (LFIAs), PCR-based diagnostic methods, and CRISPR-based diagnostics—have revolutionized the diagnosis of AMR. These innovative approaches provide increased sensitivity, reduced turnaround times, and the ability to identify genetic resistance mechanisms. This review seeks to examine the advantages and disadvantages of both emerging technologies and traditional methods for detecting AMR, emphasizing the potential benefits and limitations inherent to each. By understanding the strengths and limitations of these technologies, stakeholders, including researchers, healthcare professionals, regulatory agencies, health authorities, financial managers, and patients, can make informed decisions aimed at preventing the emergence and dissemination of antibiotic-resistant strains, thereby ultimately increasing patient safety.

Authors: Ayman Elbehiry, Eman Marzouk, Feras Alzaben, Abdulaziz Almuaither, Banan Abead, Mohammed Alamri, Abdulaziz M. Almuzaini, Akram Abu-Okail

DOI: 10.3390/microorganisms13071447

Volume13
Issue7
Pages1447
Abstract

The global consumption of fresh and ready-to-eat (RTE) fruits and vegetables has surged due to increasing awareness of their nutritional benefits. However, this trend has been accompanied by a rise in foodborne illness outbreaks linked to microbial contamination. This narrative review synthesizes current knowledge on the prevalence and diversity of foodborne pathogens in fresh produce, including bacterial, viral, and fungal agents. It critically evaluates both conventional and emerging detection methods, ranging from culture-based techniques and immunoassays to advanced molecular diagnostics, biosensors, flow cytometry (FC), and hyperspectral imaging (HSI). Additionally, this review discusses cutting-edge control strategies, such as natural antifungal agents, essential oils, biocontrol methods, and non-thermal technologies like cold plasma and UV-C treatment. Emphasis is placed on sampling methodologies, sustainability, One Health perspectives, and regulatory considerations. By highlighting recent technological advances and their limitations, this review aims to support the development of integrated, effective, and safe microbial control approaches for the fresh produce supply chain.

Authors: Ayman Elbehiry, Eman Marzouk, Adil Abalkhail, Husam M. Edrees, Abousree T. Ellethy, Abdulaziz M. Almuzaini, Mai Ibrahem, Abdulrahman Almujaidel, Feras Alzaben, Abdullah Alqrni, Akram Abu-Okail

DOI: 10.3390/microorganisms13071592

Volume13
Issue7
Pages1592
Abstract

The intersection of microbial food safety and antimicrobial resistance (AMR) represents a mounting global threat with profound implications for public health, food safety, and sustainable development. This review explores the complex pathways through which foodborne pathogens—such as Salmonella spp., Escherichia coli (E. coli), Listeria monocytogenes (L. monocytogenes), and Campylobacter spp.—acquire and disseminate resistance within human, animal, and environmental ecosystems. Emphasizing a One Health framework, we examine the drivers of AMR across sectors, including the misuse of antibiotics in agriculture, aquaculture, and clinical settings, and assess the role of environmental reservoirs in sustaining and amplifying resistance genes. We further discuss the evolution of surveillance systems, regulatory policies, and antimicrobial stewardship programs (ASPs) designed to mitigate resistance across the food chain. Innovations in next-generation sequencing, metagenomics, and targeted therapeutics such as bacteriophage therapy, antimicrobial peptides (AMPs), and CRISPR-based interventions offer promising alternatives to conventional antibiotics. However, the translation of these advances into practice remains uneven, particularly in low- and middle-income countries (LMICs) facing significant barriers to diagnostic access, laboratory capacity, and equitable treatment availability. Our analysis underscores the urgent need for integrated, cross-sectoral action—anchored in science, policy, and education—to curb the global spread of AMR. Strengthening surveillance, investing in research, promoting responsible antimicrobial use, and fostering global collaboration are essential to preserving the efficacy of existing treatments and ensuring the microbiological safety of food systems worldwide.

Authors: Ayman Elbehiry, Eman Marzouk, Husam M. Edrees, Riyad AlShaqi, Abousree T. Ellethy, Feras Alzaben, Sulaiman Anagreyyah, Ahmad Algarni, Khalid Almuhaydili, Ibrahim Alotaibi, Abdulrahman Albaqami, Khalid Alamri, Mai Ibrahem, Abdulaziz M. Almuzaini, Fali

DOI: 10.3389/fmed.2025.1596579

Volume12
Issue0
Pages1
Abstract

Tuberculosis (TB) remains one of the leading causes of infectious disease mortality worldwide, increasingly complicated by the emergence of drug-resistant strains and limitations in existing diagnostic and therapeutic strategies. Despite decades of global efforts, the disease continues to impose a significant burden, particularly in low- and middle-income countries (LMICs) where health system weaknesses hinder progress. This comprehensive review explores recent advancements in TB diagnostics, antimicrobial resistance (AMR surveillance), treatment strategies, and vaccine development. It critically evaluates cutting-edge technologies including CRISPR-based diagnostics, whole-genome sequencing, and digital adherence tools, alongside therapeutic innovations such as shorter multidrug-resistant TB regimens and host-directed therapies. Special emphasis is placed on the translational gap—highlighting barriers to real-world implementation such as cost, infrastructure, and policy fragmentation. While innovations like the Xpert MTB/RIF Ultra, BPaLM regimen, and next-generation vaccines such as M72/AS01E represent pivotal progress, their deployment remains uneven. Implementation science, cost-effectiveness analyses, and health equity considerations are vital to scaling up these tools. Moreover, the expansion of the TB vaccine pipeline and integration of AI in diagnostics signal a transformative period in TB control. Eliminating TB demands more than biomedical breakthroughs—it requires a unified strategy that aligns innovation with access, equity, and sustainability. By bridging science with implementation, and integrating diagnostics, treatment, and prevention within robust health systems, the global community can accelerate the path toward ending TB.

Authors: Ayman Elbehiry, Eman Marzouk, Husam M. Edrees, Moustafa H. Abdelsalam, Feras Aljizani, Saad Alqarni, Eyad Khateeb, Feras Alzaben, Mai Ibrahem, Ayman M. Mousa, Nasser Huraysh, Akram Abu-Okail

DOI: 10.3390/diagnostics15232944

Volume15
Issue23
Pages2944
Abstract

Bloodstream infections and sepsis necessitate rapid, sensitive, and clinically relevant diagnostics to minimize treatment delays and improve clinical outcomes. Next-generation sequencing enables culture-independent pathogen detection, antimicrobial resistance profiling, and genome-informed epidemiology. This narrative review integrates clinical evidence with practical workflows across three complementary approaches. We describe the use of plasma microbial cell-free DNA for broad organism detection and burden monitoring, as well as metagenomic next-generation sequencing of blood or plasma for unbiased pathogen discovery, including culture-negative and polymicrobial infections. Same-day Oxford Nanopore Technologies sequencing of positive blood culture broth is also discussed as a way to accelerate species identification, targeted resistance reporting, and infection-prevention decisions. We outline the sample-to-result steps, typical turnaround time (TAT), and stewardship-aligned decision points. Analytical reliability depends on effective reduction in human DNA background, stringent control of background and reagent-derived nucleic acids in low-biomass samples, and documented and validated bioinformatics workflows that are supported by curated taxonomic and resistance databases. Quantitative reports should adhere to validated thresholds and should be interpreted in the context of internal controls and clinical pretest probability. Ongoing challenges include variable correlation between genotype and phenotype for specific pathogen and antibiotic pairs, interpretation of low-level signals, and inconsistent regulatory and reimbursement environments. Advances in portable sequencing, faster laboratory and analytical workflows, and scaled liquid biopsy strategies may further reduce the TAT and expand access. Integrating these tools within One Health frameworks and global genomic surveillance programs could support early resistance detection and coordinated public health action, which could help to advance sepsis care toward more precise treatment and real-time infection control insights.

Authors: Akram Abu-Okail, Abdullah S. M. Aljohani, Ayman M. Mousa, Heba A. S. El-Nashar, Mohamed El-Shazly, Ramy K. A. Sayed, Waleed Al Abdulmonem, Mohamed Farghali, Heba F. Kamaly, Ibrahim M. El-Ashmawy, Ahmed A. H. Abdellatif, Nashwa Hamad

DOI: 10.3389/fcell.2025.1677434

Volume13
Issue1
Pages1
Abstract

Background Cadmium (Cd) is widely known as an environmental toxicant, ranked as the seventh most toxic heavy metal. Exposure to cadmium through inhalation and ingestion can lead to serious health issues, including liver damage, kidney degeneration, testicular problems, and blood disorders in both humans and animals. Objective This study aimed to evaluate the protective effects of biosynthesized silver nanoparticles (AgNPs) against cadmium chloride-induced hepatic, renal, and reproductive toxicity in male rats. Methods AgNPs were synthesized via chemical reduction in silver nitrate using a combination of three plant extracts, namely, Petroselinum crispum , Zea mays silk, and Acacia senegal . The obtained AgNPs were characterized and subjected to an in vivo study. Forty healthy adult male albino rats (200–230 g) were divided into four groups (n = 10): G1: negative control, G2: rats received AgNPs (200 mg/kg b.w), G3: rats received cadmium chloride (5 mg/kg b.w), and G4: rats received AgNPs (200 mg/kg b.w.) followed by cadmium chloride (5 mg/kg b.w) after 90 min. All treatments were administered daily for 35 days. Biochemical assessments included liver enzymes (alanine transaminase, aspartate aminotransferase, and alkaline phosphatase), kidney markers (urea and creatinine), testicular hormones (testosterone, luteinizing hormone, and follicle-stimulating hormone), lipid profile (low-density lipoprotein, high-density lipoprotein, and triglyceride), and antioxidant markers (total antioxidants and malondialdehyde). Histopathological studies were performed on the liver, kidney, and testicular tissues. Results Synthesized AgNPs exhibited spherical morphology, with an average nanosize distribution of 5.28–21.47 nm. Cadmium chloride exposure significantly elevated liver enzymes, lipid markers, urea, creatinine, and MDA while decreasing testicular hormone levels (testosterone and luteinizing hormone), indicating hepato-renal and testicular damage, alongside histopathological damage in all examined organs. Co-administration of AgNPs markedly ameliorated these biochemical alterations, improving liver and kidney function, restoring total antioxidant capacity, and normalizing lipid, protein, and testicular hormone profiles. Histopathological results revealed that treatment with AgNPs restored the angiopathic, degenerative, and necrotic changes prompted by cadmium chloride administration. Conclusion AgNPs biosynthesized from combined extracts of P. crispum , Z. mays silk, and A. senegal demonstrated significant protective effects against cadmium chloride-induced toxicity. Their antioxidant and free radical scavenging properties suggest potential therapeutic value in mitigating environmental cadmium toxicity.

Authors: Ayman Elbehiry, Eman Marzouk, Husam M. Edrees, Mai Ibrahem, Safiyah Alzahrani, Sulaiman Anagreyyah, Hussain Abualola, Abdulaziz Alghamdi, Ahmed Alzahrani, Mahmoud Jaber, Akram Abu-Okail

DOI: 10.3390/microorganisms14010109

Volume14
Issue1
Pages109
Abstract

Pseudomonas aeruginosa (P. aeruginosa) forms biofilms that are difficult to eliminate. The matrix protects the cells, efflux pumps reduce intracellular drug levels, and dormant subpopulations survive treatment. Routine minimum inhibitory concentration (MIC) testing does not account for these features, which helps explain why infections often continue even when therapy appears appropriate. This review describes how quorum-sensing (QS) and cyclic di-guanosine monophosphate (c-di-GMP) regulate matrix production, efflux activity, and dormancy within P. aeruginosa biofilms. Important matrix components, including Psl, Pel, alginate, and extracellular DNA, slow the movement of antimicrobial agents. Regulatory proteins such as sagS and brlR increase the activity of the MexAB-OprM and MexEF-OprN efflux systems, further reducing intracellular drug concentrations. Oxygen and nutrient limitation promote persister cells and viable but nonculturable cells, with both having the ability to survive antibiotic levels that would normally be lethal. These defenses explain the gap between MIC values and biofilm-specific measurements, such as the minimum biofilm inhibitory concentration and the minimum biofilm eradication concentration. This review also summarizes emerging antibiofilm strategies. These include QS inhibitors, compounds that lower c-di-GMP, such as nitric oxide donors, nanoparticles, depolymerases, bacteriophages, and therapies that are directed at host targets. Modern diagnostic tools, such as confocal laser scanning microscopy, optical coherence tomography, and Raman spectroscopy, improve detection and guide treatment planning. A staged therapeutic approach is presented that begins with the dispersal or loosening of the matrix, continues with targeted antibiotics, and concludes with support for immune clearance. Viewing these strategies within a One Health framework highlights the role of biofilms in clinical disease and in environmental reservoirs and supports more effective surveillance and prevention.

Authors: Wesam M. A. Elgendy, Hany M. El-Wahsh, Doaa Naguib, Rasha A. Elmahy, Suzan Awad AbdelGhany Morsy, Ashraf Fawzy Mosa Ahmed, Marim Fayz Abdow, Nabeel Hussain Alhussainy, Faten Abdullah Al Braikan, Ahmed Bendari, Akram Abu-Okail, Amira Mohamed AbdelHady

DOI: 10.1007/s11686-026-01244-x

Volume71
Issue2
Pages78
Abstract

Hymenolepis nana (H. nana) is a neglected zoonotic cestode that commonly infects humans and is typically treated with praziquantel (PZQ). Due to concerns about drug resistance and adverse effects, this study explored the antiparasitic activity of aqueous extracts from Artemisia alba, Moringa oleifera, and Ceratonia siliqua, as well as their corresponding silver-nanoparticles (AgNPs)-loaded extracts, against H. nana infection.

No matching articles

Try another word from the title, author or DOI.

Brief Bio

Akram Abu-Okail is currently a PhD researcher at Cairo University, Faculty of Veterinary Medicine, Department of Clinical Pathology. Akram is a M.Sc. graduated student from Qassim University, College of Veterinary Medicine, Department of Pathology and Laboratory Diagnosis, Laboratory Diagnosis Program. Akram does research in Clinical and Molecular Pathology. I am looking for potential International collaborators to work on joint research projects on clinical and molecular pathology.

Affiliations

Nothing added yet.

Education

Nothing added yet.

Honors & Awards

Nothing added yet.

Society Memberships

Nothing added yet.

Expertise

Nothing added yet.

Specialty

Nothing added yet.

Suggested researchers

Muheebur Rehman
Abasyn University Peshawar
23 publications
Somchai Amornyotin
Department of Anesthesiology, Faculty of Medicine Siriraj Hospital, Mahidol University
108 publications
Dr. Vikash Mishra
Chimera Transplant Research Foundation
58 publications
EE
Ehab Elsaih
Department of Prosthodontics, College of Dentistry, The Islamic University in Najaf, Najaf, Iraq.
20 publications
DK
Dinesh Kansal
D
20 publications
SM
Syeed Mehbub Ul Kadir
A
16 publications
VK
Vishnu Kumar Gupta
University of Rajasthan, Jaipur
20 publications
HA
Himanshu Aeran
Seema Dental College and Hospital, Rishikesh, Uttarakhand, India
18 publications
Fathi M Sherif
University of Tripoli, Pharmacy, Pharmacology
31 publications
Dr. Dukre Tushar Pradip
College of Pharmaceutical Sciences, PIMS (DU), Loni.
34 publications
RG
Rajat Goyal
MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala
29 publications
Ghouse Modin Mamdapur
Information and Documentation
30 publications

Following

Nobody here yet.

Followers

Nobody here yet.

16 Publications